Adebrelimab in combination with dalpiciclib and endocrine therapy as neoadjuvant treatment for HR+/HER2− early breast cancer: an exploratory study
This triplet regimen demonstrated modest clinical activity in HR+/HER2- early BC, with the safety profile of this regimen remains a concern and warrants particular attention in clinical practice.
Authors
- Tong Liu (ORCID: https://orcid.org/0000-0001-9234-1328)
- Bo Lei (ORCID: https://orcid.org/0000-0002-5613-5233)
- Crystal Song Zhang
- Jinsong Wang
- He Ren
- Fanxuan Huang
- Xinhao Han
- Min Xiao
Institutions
- Emory University (US)
- Harbin Medical University (CN)
- Third Affiliated Hospital of Harbin Medical University (CN)
- Education Department of Heilongjiang Province (CN)
Publication Details
- Journal
- International Journal of Surgery
- Published
- 2026-02-23
- DOI
- https://doi.org/10.1097/js9.0000000000004982
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00